https://www.traderplanet.com/nokia-hurt-by-impairment-charges-analyst-blog/
Nokia Hurt by Impairment Charges - Analyst Blog - TraderPlanet
Oct 15, 2009 - Nokia Corp. (NOK) today declared financial results for the third quarter of fiscal 2009. Total revenue of Euro 9.8 billion was a decrease of 19.8%...
impairment chargesanalyst blognokiahurt
https://trendsmena.com/tag/impairment-charges/
Impairment Charges Archives - TRENDS MENA
impairment chargesarchivestrendsmena
https://businessmetricsng.com/first-holdco-plc-grows-earnings-to-n3-4-trillion-profit-declines-on-heavier-impairment-charges/
First HoldCo Plc Grows Earnings to N3.4 Trillion, Profit Declines on Heavier Impairment Charges -...
Feb 2, 2026 - First HoldCo Plc has reported stronger topline performance in its unaudited financial results for the 2025 financial year, with gross earnings rising by 4.8...
first holdcoimpairment chargesplcgrowsearnings
https://www.sharesansar.com/newsdetail/muktinath-bikas-bank-achieves-813-increase-in-q3-net-profit-eps-at-rs-1650-impairment-charges-decrease-by-640-2024-04-19?skip=true
Muktinath Bikas Bank Achieves 8.13% Increase in Q3 Net Profit; EPS at Rs. 16.50, Impairment Charges...
Dec 15, 2016 - || ShareSansar || Muktinath Bikas Bank Limited (MNBBL) has recently disclosed its unaudited financial statement for the third quarter of the fiscal year...
net profitimpairment chargesmuktinathbankincrease
https://www.cityam.com/vanquis-bank-swings-to-annual-loss-and-slashes-dividend-after-jump-in-impairment-charges/
Vanquis swings to loss and slashes dividend on jump in impairment charges
Mar 27, 2024 - Vanquis Banking Group has swung to an annual loss after the specialist lender saw a jump in impairment charges, following a profit warning for 2024 earlier...
jump inimpairment chargesswingslossslashes
https://marketexclusive.com/credit-suisse-nysecs-suffers-loss-in-4q-on-impairment-charges/2016/02/
Credit Suisse (NYSE:CS) Suffers Loss in Q4 on Impairment Charges | Market Exclusive
credit suisseimpairment chargesnysecsloss
https://www.fiercebiotech.com/biotech/j-j-discontinues-work-eczema-drug-leading-to-610m-impairment-charges-for-ex-xbiotech-asset
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset...
leading toimpairment chargesjworkeczema